Achillion has ended speculation (some of it self-generated) that it is fending off potential acquisitors from within the hepatitis C space by signing a significant collaboration with Johnson & Johnson's Janssen unit. J&J will be hoping that the deal catapults it to the front of the pack in the development of ultra-short-duration, pan-genotypic hepatitis C treatments.
J&J banks on Achillion for leg up in next-generation hep C drug race
Achillion has ended speculation (some of it self-generated) that it is fending off potential acquisitors from within the hepatitis C space by signing a significant collaboration with Johnson & Johnson's Janssen unit. J&J will be hoping that the deal catapults it to the front of the pack in the development of ultra-short-duration, pan-genotypic hepatitis C treatments.
More from Business
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
More from Scrip
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.